Release Date: 15-Jul-2024
MedImmune’s Volrustomig (MEDI5752) is a new bispecific antibody that targets the immunological checkpoints programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4). Following the acquisition of MedImmune by AstraZeneca, the latter has been spearheading the clinical development of Volrustomig in a variety of solid tumors. Volrustomig, which is currently in phase III clinical studies, is expected to compete with Akeso’s Cadonilimab, the first and only dual immune checkpoint inhibiting bispecific antibody in the market.
In multiple preclinical models and clinical trials, the combination of PD-1/CTLA-4 inhibition has been demonstrated to increase survival for several advanced stage solid tumors. Volrustomig combines the functions of individual PD-1 and CTLA-4 inhibitory antibodies into one; it acts by targeting both PD-1 and CTLA-4 at the same time. Volrustomig attempts to activate the immune system by blocking these checkpoints, allowing T cells to mount a more effective and coordinated attack against cancer cells. This dual targeting technique is intended to boost the antitumor immune response.
Volrustomig distinguishes itself from other bispecific antibodies by being an antibody that targets both PD-1 and CTLA-4. While monotherapies targeting PD-1 or CTLA-4 have shown clinical efficacy, combining these effects into a single medication like Volrustomig has the potential to amplify the therapeutic effect, providing a more holistic approach to cancer treatment. On activated PD-1+ T cells, Volrustomig achieves complete PD-1 blockage as well as selective CTLA-4 suppression. Volrustomig, as a dual immune checkpoint inhibitor, also has the potential to replace first-generation checkpoint inhibitors in a variety of malignancies.
Late-stage clinical trials for Volrustomig include cancer indications such as cervical cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, and pleural mesothelioma. Despite the fact that no clinical trials results for Volrustomig have been announced in recent months, early clinical trial findings for the candidate have been positive, with signs of increased response rates and long-term antitumor activity. Dual PD-1 and CTLA-4 inhibition appears to unlock synergistic effects, thereby extending the range of patients who may benefit from this immunotherapy.
Volrustomig’s benefits and market impact are highly awaited as it advances through clinical studies. Its importance in the pharmaceutical industry stems from its potential to change the landscape of cancer treatment by providing a more potent and tailored therapeutic option. However, difficulties like managing immune-related adverse events and improving dosage regimens necessitate careful thought.
For Clinical Trials Information Contact [email protected]